ArticleRenal failure2025
Association of cystatin C with 20-year mortality risk in the general US population: a cohort study.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpaired kidney function is associated with increased mortality. This study evaluated the association between serum cystatin C levels and long-term all-cause, cardiovascular, and cerebrovascular mortality in the general U.S. population.
methodsImpaired kidney function is associated with increased mortality. This study evaluated the association between serum cystatin C levels and long-term all-cause, cardiovascular, and cerebrovascular mortality in the general U.S. population.
resultsDuring a median follow-up of 207 months (interquartile range [IQR]: 188.0-227.0), 3,538 participants died. The median baseline age was 44.0 years (IQR: 33.0-57.0). Participants were categorized into quintiles based on serum cystatin C, creatinine, and estimated glomerular filtration rate (eGFR). Multivariate analysis, revealed a significant association of cystatin C's third, fourth, and fifth quintiles with an increased risk of all-cause mortality. Compared to the first quintile, the hazard ratios (HR) [95% confidence intervals (CI)] for all-cause mortality were as follows: second quintile, 1.05 (0.82-1.34); third quintile, 1.29 (1.03-1.60); fourth quintile, 1.46 (1.17-1.83); and fifth quintile, 2.32 (1.86-2.89). Furthermore, the second quintile had a 1.78-fold risk (HR: 1.78, 95%CI: 1.11-2.86), the fourth quintile had a 1.85-fold risk (HR: 1.85, 95% CI: 1.17-2.92), and the fifth quintile had a 2.97-fold risk of cardiovascular mortality (HR: 2.97, 95% CI: 1.89-4.68). However, adjusted analysis did not reveal creatinine and eGFR as predictors for any outcome. After adjusting for confounding factors, creatinine and eGFR were not significantly associated with the risk of death.
conclusionCystatin C emerged as an independent predictor of all-cause and cardiovascular mortality with in the general population of the US.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.